Crestor rosuvastatin: Additional Phase III data

Additional data from the double-blind, international Phase III JUPITER trial in 17,802 patients showed that 20 mg Crestor significantly reduced cardiovascular events by 63% in patients who achieved a very low LDL-C (<50 mg/dL) vs. placebo (p<0.0001). In a subgroup of 6,801 women without cardiovascular disease but at increased risk of a cardiovascular event as determined by age and elevated high-sensitivity C-reactive protein (hsCRP), Crestor significantly reduced cardiovascular events by 46% vs. placebo (p=0.002). In a subgroup of 5,466 patients with impaired fasting glucose at baseline, Crestor significantly reduced the risk of cardiovascular events by 32% vs. placebo (p=0.028). Data were presented at the American Heart Association meeting in Orlando. ...